Study on gastrointestinal and hepatic side effects induced by immunity checkpoint inhibitors

Study on gastrointestinal and hepatic side effects induced by immunity checkpoint inhibitors - Analysis of gastrointestinal and hepatic side effects induced by immunity checkpoint inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037174

Enrollment

Registered

2019-08-01

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients treated with immune checkpoint inhibitors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who developed Grade 2 or higher digestive-related adverse events using immune checkpoint inhibitors at our hospital Patients who understood the contents of this study and obtained written consent to participate in the study

Exclusion criteria

Exclusion criteria: Patients wishing to be excluded from the study If the principal investigator or co-investigator determines that the research participation is ineligible for other reasons

Design outcomes

Primary

Measure	Time frame
Examination of clinical,endoscopic and histopathological features of irAE	—

Secondary

Measure	Time frame
Examination of factors related to the severity of irAE and treatment response	—

Countries

Japan

Contacts

Public ContactTsunaki Sawada

Nagoya University Gastroenterology and Hepatology

t.sawada@med.nagoya-u.ac.jp052-744-2172

Outcome results